• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型5-杂芳基氨基甲酰基氨基吡唑并[4,3-e]1,2,4-三唑并[1,5-c]嘧啶系列作为人A3腺苷受体拮抗剂的合成与生物学研究。杂芳基取代基对结合亲和力的影响及分子模拟研究。

Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.

作者信息

Pastorin Giorgia, Da Ros Tatiana, Bolcato Chiara, Montopoli Christian, Moro Stefano, Cacciari Barbara, Baraldi Pier Giovanni, Varani Katia, Borea Pier Andrea, Spalluto Giampiero

机构信息

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Trieste, Piazzale Europa 1, I-34127 Trieste, Italy.

出版信息

J Med Chem. 2006 Mar 9;49(5):1720-9. doi: 10.1021/jm051147+.

DOI:10.1021/jm051147+
PMID:16509587
Abstract

Some pyrazolotriazolopyrimidines bearing different heteroarylcarbamoylamino moieties at the N5-position are described. We previously reported the synthesis of a water soluble compound with high potency and selectivity versus the human A3 adenosine receptor as antagonist, and herein we present an enlarged series of compounds related to the previously mentioned one. These compounds showed A3 adenosine receptor affinity in the nanomolar range and different levels of selectivity evaluated in radioligand binding assays at human A1, A2A, A2B, and A3 adenosine receptors. In particular, the effect of the heteroaryl substituents at the N5 position has been analyzed. This study allows us to recognize that the presence of a pyridinium moiety in this position not only increases water solubility but also improves or retains potency and selectivity at the human A3 adenosine receptors. In contrast, replacement of pyridine with different heterocycles produces loss of affinity and selectivity at the human A3 adenosine receptors. A molecular modeling study has been carried out with the aim to explain these various binding profiles.

摘要

描述了一些在N5位带有不同杂芳基氨基甲酰基氨基部分的吡唑并三唑并嘧啶。我们之前报道了一种对人A3腺苷受体具有高效力和选择性的水溶性化合物作为拮抗剂的合成,在此我们展示了与前述化合物相关的一系列更多的化合物。这些化合物在纳摩尔范围内显示出对A3腺苷受体的亲和力,并且在人A1、A2A、A2B和A3腺苷受体的放射性配体结合试验中评估了不同程度的选择性。特别地,分析了N5位杂芳基取代基的影响。这项研究使我们认识到该位置吡啶鎓部分的存在不仅增加了水溶性,而且提高或保留了对人A3腺苷受体的效力和选择性。相反,用不同杂环取代吡啶会导致对人A3腺苷受体亲和力和选择性的丧失。为了解释这些不同的结合模式,进行了分子模拟研究。

相似文献

1
Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.新型5-杂芳基氨基甲酰基氨基吡唑并[4,3-e]1,2,4-三唑并[1,5-c]嘧啶系列作为人A3腺苷受体拮抗剂的合成与生物学研究。杂芳基取代基对结合亲和力的影响及分子模拟研究。
J Med Chem. 2006 Mar 9;49(5):1720-9. doi: 10.1021/jm051147+.
2
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.吡唑并[4,3-e]-1,2,4-三唑并[1,5-c]嘧啶衍生物作为腺苷受体拮抗剂。N5取代基对人A3和A2B腺苷受体亚型亲和力的影响:分子模拟研究。
J Med Chem. 2003 Sep 25;46(20):4287-96. doi: 10.1021/jm030852k.
3
The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.2-呋喃环取代 2-(对位取代)芳基在一系列新型吡唑并三唑嘧啶中的意义作为有效的和高度选择性的 hA(3) 腺苷受体拮抗剂:对结构-亲和力关系和受体-拮抗剂识别的新见解。
J Med Chem. 2010 Apr 22;53(8):3361-75. doi: 10.1021/jm100049f.
4
Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.新型 A2A 和 A3 腺苷受体拮抗剂 C9 和 C2 取代的吡唑并[4,3-e]-1,2,4-三唑并[1,5-c]嘧啶的设计、合成及生物学评价
J Med Chem. 2003 Mar 27;46(7):1229-41. doi: 10.1021/jm021023m.
5
Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.采用分子简化方法探索人 A3 腺苷受体拮抗剂的结合模式:从三唑并喹喔啉到嘧啶骨架的关键研究
J Med Chem. 2007 Dec 27;50(26):6596-606. doi: 10.1021/jm070852a. Epub 2007 Nov 30.
6
Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.第二代吡唑并[4,3-e]-1,2,4-三唑并[1,5-c]嘧啶作为强效和选择性A2A腺苷受体拮抗剂的设计、合成及生物学评价
J Med Chem. 1998 Jun 4;41(12):2126-33. doi: 10.1021/jm9708689.
7
Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models.基于药效团的受体建模:腺苷A3受体拮抗剂的案例。一种优化蛋白质模型的方法。
J Med Chem. 2006 Jul 13;49(14):4085-97. doi: 10.1021/jm051112+.
8
5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.5-氨基-2-苯基[1,2,3]三唑并[1,2-a][1,2,4]苯并三嗪-1-酮:一种用于获得强效和选择性A3腺苷受体拮抗剂的多功能骨架。
J Med Chem. 2007 Nov 15;50(23):5676-84. doi: 10.1021/jm0708376. Epub 2007 Oct 10.
9
1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.1,2,4-三唑并[4,3-a]喹喔啉-1-酮部分作为开发新型强效和选择性人A3腺苷受体拮抗剂的有吸引力的骨架:合成、药理学及配体-受体模型研究
J Med Chem. 2004 Jul 1;47(14):3580-90. doi: 10.1021/jm031136l.
10
Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites.使用集成支持向量机(SVM)方法结合选择性和亲和力预测:一种区分人腺苷A(2A)和A(3)受体吡唑并三唑并嘧啶拮抗剂结合位点的替代工具。
Bioorg Med Chem. 2009 Jul 15;17(14):5259-74. doi: 10.1016/j.bmc.2009.05.038. Epub 2009 May 21.

引用本文的文献

1
Potent and selective A adenosine receptor antagonists bearing aminoesters as heterobifunctional moieties.带有氨基酯作为异双功能部分的强效且选择性的 A 型腺苷受体拮抗剂。
RSC Med Chem. 2020 Dec 14;12(2):254-262. doi: 10.1039/d0md00380h. eCollection 2021 Mar 4.
2
Conjugable A adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes.可共轭的 A 型腺苷受体拮抗剂用于功能化配体的开发及其在荧光探针中的应用。
Eur J Med Chem. 2020 Jan 15;186:111886. doi: 10.1016/j.ejmech.2019.111886. Epub 2019 Nov 22.
3
Pyrazolo derivatives as potent adenosine receptor antagonists: an overview on the structure-activity relationships.
作为强效腺苷受体拮抗剂的吡唑并衍生物:构效关系概述
Int J Med Chem. 2011;2011:480652. doi: 10.1155/2011/480652. Epub 2011 Mar 7.
4
A new and efficient method for the synthesis of novel 3-acetyl coumarins oxadiazoles derivatives with expected biological activity.一种新的、高效的方法,用于合成具有预期生物活性的新型 3-乙酰香豆素噁二唑衍生物。
Molecules. 2014 Jan 14;19(1):911-24. doi: 10.3390/molecules19010911.
5
Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.A3腺苷受体的药物化学:激动剂、拮抗剂与受体工程
Handb Exp Pharmacol. 2009(193):123-59. doi: 10.1007/978-3-540-89615-9_5.
6
Syntheses of diheterocyclic compounds based on 2-thioacetohydrazide-5,7-dimethyl-1,2,4-triazolo[1,5-a]- pyrimidine.基于2-硫代乙酰肼-5,7-二甲基-1,2,4-三唑并[1,5-a]嘧啶的二杂环化合物的合成
Molecules. 2008 Jun 13;13(6):1353-60. doi: 10.3390/molecules13061353.
7
Invited Lectures : Overviews Purinergic signalling: past, present and future.特邀讲座:综述 嘌呤能信号传导:过去、现在与未来。
Purinergic Signal. 2006 May;2(1):1-324. doi: 10.1007/s11302-006-9006-2. Epub 2006 May 15.
8
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile.吡唑并三唑并嘧啶作为腺嘌呤受体拮抗剂:完整的构效关系。
Purinergic Signal. 2007 Jun;3(3):183-93. doi: 10.1007/s11302-006-9027-x. Epub 2006 Nov 14.
9
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes.吡唑并三唑并嘧啶作为腺苷受体拮抗剂:N-5 键类型对四种腺苷受体亚型的亲和力和选择性的影响。
Purinergic Signal. 2008 Mar;4(1):39-46. doi: 10.1007/s11302-007-9058-y. Epub 2007 Jul 25.